WuXi Advanced Therapies - Accelerating Progress and Time to Market • Integrated Manufacturing and Testing Service Platform • Solutions From Gene of Interest to Global Commercial Launch The advanced therapies business unit of WuXi AppTec is a leading cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Testing, Development and Manufacturing Organization (CTDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing.
View Top Employees from WuXi Advanced TherapiesWebsite | https://advancedtherapies.com |
Revenue | $62 million |
Employees | 455 (455 on RocketReach) |
Founded | 2004 |
Address | 4751 League Island Blvd, Philadelphia, Pennsylvania 19112, US |
Technologies |
JavaScript,
HTML,
PHP
+32 more
(view full list)
|
Industry | Therapeutics, Biotechnology Research, Cell Therapy, Gene Therapy, Process Development, Cell Banking, Virology, Autologous , Allogeneic, CAR-T, CDMO, CMO, Contract Manufacturing, Biomanufacturing, Bioprocessing, Antibody Drug Conjugate, Viral Vector, Biotechnology, Protein Therapeutic, Viral Clearance, Biologics, Biotherapeutics, Immunotherapy, Laboratory Testing, Preclinical Safety, Cell Line Characterization, Adventitious Agent Testing, Product Packaging, Lot Release, Analytical Development, Vaccine Manufacturing, Extractables & Leachables |
NAICS | NAICS Code 812 Companies, NAICS Code 8121 Companies, NAICS Code 81 Companies, NAICS Code 81211 Companies, NAICS Code 812112 Companies |
Looking for a particular WuXi Advanced Therapies employee's phone or email?
The WuXi Advanced Therapies annual revenue was $62 million in 2024.
David Chang is the President and Chief Technology Officer of WuXi Advanced Therapies.
455 people are employed at WuXi Advanced Therapies.
WuXi Advanced Therapies is based in Philadelphia, Pennsylvania.
The NAICS codes for WuXi Advanced Therapies are [812, 8121, 81, 81211, 812112].